Business · 14/01/2015Updated: 10/17/2026 · 1 min read
FDA Announces Opportunity for Hearing on Proposal to Revoke CHEMBIOMED's U.S. License for Anti-A and Anti-B Monoclonal Antibodies
The FDA is seeking public input on a proposal to revoke CHEMBIOMED's U.S. license for manufacturing Anti-A and Anti-B monoclonal antibodies, citing the company's discontinuation of operations and licensed product manufacturing